300204 舒泰神
已收盘 08-27 15:00:00
资讯
新帖
简况
图解舒泰神中报:第二季度单季净利润同比增100.33%
证券之星 · 08-26 17:13
图解舒泰神中报:第二季度单季净利润同比增100.33%
舒泰神(300204.SZ)发布上半年业绩,净亏损342.3万元
智通财经 · 08-26 15:50
舒泰神(300204.SZ)发布上半年业绩,净亏损342.3万元
舒泰神(300204)8月19日主力资金净卖出2240.35万元
证券之星 · 08-19
舒泰神(300204)8月19日主力资金净卖出2240.35万元
舒泰神(300204.SZ):STSP-0902注射液(用于治疗少弱精子症)Ia期临床试验完成首例受试者给药
智通财经 · 08-15
舒泰神(300204.SZ):STSP-0902注射液(用于治疗少弱精子症)Ia期临床试验完成首例受试者给药
舒泰神(300204)8月15日主力资金净买入598.90万元
证券之星 · 08-15
舒泰神(300204)8月15日主力资金净买入598.90万元
舒泰神:目前公司暂无TCR-T类在研项目。治疗艾滋病的细胞治疗药物处于临床前研究阶段
证券之星 · 08-14
舒泰神:目前公司暂无TCR-T类在研项目。治疗艾滋病的细胞治疗药物处于临床前研究阶段
A股医药板块午后局部活跃,香雪制药涨超12%,股价再创年内新高,凯普生物、贝瑞基因、舒泰神、百花医药等跟涨。
美港电讯 · 08-14
A股医药板块午后局部活跃,香雪制药涨超12%,股价再创年内新高,凯普生物、贝瑞基因、舒泰神、百花医药等跟涨。
舒泰神最新公告:香塘集团拟减持不超过1%
证券之星 · 08-13
舒泰神最新公告:香塘集团拟减持不超过1%
舒泰神(300204.SZ)股东香塘集团拟减持不超1%股份
智通财经 · 08-13
舒泰神(300204.SZ)股东香塘集团拟减持不超1%股份
【舒泰神:香塘集团拟减持不超过1%】金十数据8月13日讯,舒泰神公告,持有公司4147.27万股的香塘集团有限公司计划在公告披露之日起15个交易日后的3个月内,通过集中竞价方式减持不超过477.
美港电讯 · 08-13
【舒泰神:香塘集团拟减持不超过1%】金十数据8月13日讯,舒泰神公告,持有公司4147.27万股的香塘集团有限公司计划在公告披露之日起15个交易日后的3个月内,通过集中竞价方式减持不超过477.
【A股午评:沪指跌0.07% 油气开采概念涨幅居前】金十数据8月13日讯,A股三大指数早盘窄幅震荡,截至午间收盘,上证指数跌0.
美港电讯 · 08-13
【A股午评:沪指跌0.07% 油气开采概念涨幅居前】金十数据8月13日讯,A股三大指数早盘窄幅震荡,截至午间收盘,上证指数跌0.
A股新冠特效药概念回调,舒泰神跌超6%,红日药业、精华制药、之江生物、睿智医药等跟跌。
美港电讯 · 08-13
A股新冠特效药概念回调,舒泰神跌超6%,红日药业、精华制药、之江生物、睿智医药等跟跌。
舒泰神(300204)8月12日主力资金净买入1657.00万元
证券之星 · 08-12
舒泰神(300204)8月12日主力资金净买入1657.00万元
舒泰神(300204)8月9日主力资金净卖出2241.33万元
证券之星 · 08-09
舒泰神(300204)8月9日主力资金净卖出2241.33万元
舒泰神最新公告:STSA-1301皮下注射液取得Ia期临床研究总结报告
证券之星 · 08-08
舒泰神最新公告:STSA-1301皮下注射液取得Ia期临床研究总结报告
舒泰神(300204.SZ):STSA-1301皮下注射液取得Ia期临床研究总结报告
智通财经网 · 08-08
舒泰神(300204.SZ):STSA-1301皮下注射液取得Ia期临床研究总结报告
舒泰神:取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。
美港电讯 · 08-08
舒泰神:取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。
舒泰神(300204)8月8日主力资金净买入220.80万元
证券之星 · 08-08
舒泰神(300204)8月8日主力资金净买入220.80万元
A股医药股集体走弱 CRO方向领跌河化股份、百花医药跌停,睿智医药、双成药业、金凯生科、鲁抗医药、四环生物、舒泰神等多股跌超5%。
格隆汇 · 08-07
A股医药股集体走弱 CRO方向领跌河化股份、百花医药跌停,睿智医药、双成药业、金凯生科、鲁抗医药、四环生物、舒泰神等多股跌超5%。
舒泰神(300204)8月6日主力资金净买入314.52万元
证券之星 · 08-06
舒泰神(300204)8月6日主力资金净买入314.52万元
暂无数据
公司概况
公司名称:
舒泰神(北京)生物制药股份有限公司
所属行业:
医药制造业
上市日期:
2011-04-15
主营业务:
舒泰神(北京)生物制药股份有限公司以自主知识产权创新药物的研发、生产和营销为主要业务,致力于研发、生产和销售临床需求未被满足的治疗性药物,主要包括蛋白类药物(含治疗性单克隆抗体药物)、基因治疗/细胞治疗药物、化学药物三大药物类别,治疗领域覆盖了神经系统相关疾病、感染性疾病、胃肠道疾病、泌尿系统疾病以及自身免疫系统疾病等多种领域。公司上市销售产品为创新生物药物苏肽生(注射用鼠神经生长因子)和全国独家品种舒泰清(复方聚乙二醇电解质散(IV))。苏肽生是我国神经生长因子领域第一个国药准字号产品,是具有自主知识产权的国家一类新药,适应症为“具有促进神经损伤恢复的作用。用于治疗视神经损伤”。苏肽生的两项研发课题被列为“国家十二五重大新药创制项目”;获得北京市科学技术进展三等奖;苏肽生的产业化被列为国家发改委“国家高技术产业发展项目”、国家发改委和经信委联合审评的“重点产业振兴和技术改造专项项目”。
发行价格:
52.50
{"stockData":{"symbol":"300204","market":"SZ","secType":"STK","nameCN":"舒泰神","latestPrice":6.38,"timestamp":1724742216000,"preClose":6.47,"halted":0,"volume":13719335,"delay":0,"floatShares":472000000,"shares":478000000,"eps":-0.521,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.09,"latestTime":"08-27 15:00:00","open":6.5,"high":6.8,"low":6.32,"amount":89982200,"amplitude":0.0742,"askPrice":6.38,"askSize":103,"bidPrice":6.37,"bidSize":379,"shortable":0,"etf":0,"ttmEps":-0.521,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724808600000},"adr":0,"adjPreClose":6.47,"symbolType":"stock","openAndCloseTimeList":[[1724722200000,1724729400000],[1724734800000,1724742000000]],"highLimit":7.12,"lowLimit":5.82,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":477772555,"pbRate":2.95,"roa":"--","roe":"--","epsLYR":-0.84,"committee":0.265388,"marketValue":3048000000,"floatMarketCap":3009000000,"peRate":-12.245681,"changeRate":-0.0139,"turnoverRate":0.0291,"status":1},"requestUrl":"/m/hq/s/300204/tweets","defaultTab":"tweets","newsList":[{"id":"2462667939","title":"图解舒泰神中报:第二季度单季净利润同比增100.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462667939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462667939?lang=zh_cn&edition=full","pubTime":"2024-08-26 17:13","pubTimestamp":1724663618,"startTime":"0","endTime":"0","summary":"证券之星消息,舒泰神2024年中报显示,公司主营收入1.82亿元,同比上升7.69%;归母净利润-342.3万元,同比上升97.77%;扣非净利润-637.4万元,同比上升95.88%;其中2024年第二季度,公司单季度主营收入8740.64万元,同比下降16.24%;单季度归母净利润34.64万元,同比上升100.33%;单季度扣非净利润-193.48万元,同比上升98.16%;负债率19.42%,投资收益-17.63万元,财务费用22.28万元,毛利率82.32%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082600023545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204"],"gpt_icon":0},{"id":"2462521059","title":"舒泰神(300204.SZ)发布上半年业绩,净亏损342.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462521059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462521059?lang=zh_cn&edition=full","pubTime":"2024-08-26 15:50","pubTimestamp":1724658638,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神 发布2024年半年度报告,报告期内,公司实现营业收入1.82亿元,同比增长7.69%。归属于上市公司股东净亏损342.3万元,同比减亏97.77%。报告期内,公司生产经营活动较为有序开展。同时,基于未来研发项目整体布局和公司发展战略考虑,公司将资源投入重点聚焦至临床阶段研发项目的推进,报告期内研发费用5,829.85万元,较去年同期下降70.39%。基于上述原因,公司业绩承压,报告期净利润为负值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1170442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300204","BK0239","BK0046"],"gpt_icon":0},{"id":"2460069817","title":"舒泰神(300204)8月19日主力资金净卖出2240.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460069817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460069817?lang=zh_cn&edition=full","pubTime":"2024-08-19 15:23","pubTimestamp":1724052195,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月19日收盘,舒泰神报收于6.93元,下跌4.41%,换手率3.96%,成交量18.67万手,成交额1.3亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:舒泰神2024年一季报显示,公司主营收入9498.34万元,同比上升46.09%;归母净利润-376.94万元,同比上升92.26%;扣非净利润-443.92万元,同比上升90.99%;负债率21.56%,投资收益-6.59万元,财务费用8.88万元,毛利率83.72%。舒泰神主营业务:自主知识产权创新药物,特别是生物药物的研发、生产和营销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900013497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0028","BK0239"],"gpt_icon":0},{"id":"2459412745","title":"舒泰神(300204.SZ):STSP-0902注射液(用于治疗少弱精子症)Ia期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2459412745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459412745?lang=zh_cn&edition=full","pubTime":"2024-08-15 16:39","pubTimestamp":1723711174,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神(300204.SZ)公告,公司于2024年6月收到了国家药品监督管理局签发的STSP-0902注射液用于治疗少弱精子症的《药物临床试验批准通知书》,同意本品开展少弱精子症的临床试验。近日,STSP-0902注射液在北京大学第三医院完成了针对少弱精子症Ia期临床试验的首例受试者给药,实验题目为:随机、双盲、安慰剂对照、单剂量递增评价STSP-0902注射液在健康受试者中的安全性、耐受性、药代动力学特征及免疫原性的Ia期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1164606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0239","BK0028","BK1583","300204","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2459166484","title":"舒泰神(300204)8月15日主力资金净买入598.90万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459166484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459166484?lang=zh_cn&edition=full","pubTime":"2024-08-15 15:24","pubTimestamp":1723706650,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月15日收盘,舒泰神报收于7.62元,下跌1.04%,换手率6.07%,成交量28.61万手,成交额2.2亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:舒泰神2024年一季报显示,公司主营收入9498.34万元,同比上升46.09%;归母净利润-376.94万元,同比上升92.26%;扣非净利润-443.92万元,同比上升90.99%;负债率21.56%,投资收益-6.59万元,财务费用8.88万元,毛利率83.72%。舒泰神主营业务:自主知识产权创新药物,特别是生物药物的研发、生产和营销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081500025670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300204","BK0239"],"gpt_icon":0},{"id":"2459595121","title":"舒泰神:目前公司暂无TCR-T类在研项目。治疗艾滋病的细胞治疗药物处于临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2459595121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459595121?lang=zh_cn&edition=full","pubTime":"2024-08-14 19:02","pubTimestamp":1723633351,"startTime":"0","endTime":"0","summary":"目前公司暂无TCR-T类在研项目。治疗艾滋病的细胞治疗药物处于临床前研究阶段。STSP-0601项目已完成伴抑制物的血友病A或B患者出血按需治疗的Ib/II期临床研究,以及不伴抑制物的血友病A或B患者出血按需治疗的II期临床研究;目前正在开展伴抑制物的血友病A或B患者出血按需治疗的IIb期临床研究。有关公司研发管线及研发项目进展,敬请关注公司定期报告及项目进展公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400038985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300204","BK0239"],"gpt_icon":0},{"id":"2459451190","title":"A股医药板块午后局部活跃,香雪制药涨超12%,股价再创年内新高,凯普生物、贝瑞基因、舒泰神、百花医药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459451190","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459451190?lang=zh_cn&edition=full","pubTime":"2024-08-14 13:10","pubTimestamp":1723612207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159938","BK0239","BK0102","BK0070","BK0221","BK1574","BK0042","600721","09939","BK0046","300639","399300","BK0132","300204","159982","BK0216","300147","BK0139","BK1515","BK0060","BK0081","BK1161","BK0028","BK0086","000710"],"gpt_icon":0},{"id":"2459977317","title":"舒泰神最新公告:香塘集团拟减持不超过1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459977317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459977317?lang=zh_cn&edition=full","pubTime":"2024-08-13 20:00","pubTimestamp":1723550420,"startTime":"0","endTime":"0","summary":"舒泰神公告,持有公司4147.27万股的香塘集团有限公司计划在公告披露之日起15个交易日后的3个月内,通过集中竞价方式减持不超过477.77万股。(占总股本的1%)以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081300040134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300204","BK0028"],"gpt_icon":0},{"id":"2459972333","title":"舒泰神(300204.SZ)股东香塘集团拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2459972333","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459972333?lang=zh_cn&edition=full","pubTime":"2024-08-13 19:54","pubTimestamp":1723550049,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神(300204.SZ)发布公告,公司股东香塘集团有限公司计划自本公告披露之日起15个交易日后的3个月内,以集中竞价方式减持公司股份不超过477.77万股(约占公司总股本的1%)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","300204","BK0046"],"gpt_icon":0},{"id":"2459997906","title":"【舒泰神:香塘集团拟减持不超过1%】金十数据8月13日讯,舒泰神公告,持有公司4147.27万股的香塘集团有限公司计划在公告披露之日起15个交易日后的3个月内,通过集中竞价方式减持不超过477.","url":"https://stock-news.laohu8.com/highlight/detail?id=2459997906","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459997906?lang=zh_cn&edition=full","pubTime":"2024-08-13 19:24","pubTimestamp":1723548268,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0046","BK0028","300204","BK0239"],"gpt_icon":0},{"id":"2459915259","title":"【A股午评:沪指跌0.07% 油气开采概念涨幅居前】金十数据8月13日讯,A股三大指数早盘窄幅震荡,截至午间收盘,上证指数跌0.","url":"https://stock-news.laohu8.com/highlight/detail?id=2459915259","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459915259?lang=zh_cn&edition=full","pubTime":"2024-08-13 11:35","pubTimestamp":1723520121,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0214","300157","002629","399001","605218","BK0177","159982","399006","001314","BK0029","BK0102","399300","YXI","BK0004","BK0172","300204","BK0046","BK0028","BK0188","002952","159732","002349","161024","BK0071","BK0144","CNmain","000300.SH","BK0258","000001.SH","BK0077","BK0176","161121","512550","510030","XPP","002207","000016.SH","FXP","510050","BK0239"],"gpt_icon":0},{"id":"2459992896","title":"A股新冠特效药概念回调,舒泰神跌超6%,红日药业、精华制药、之江生物、睿智医药等跟跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459992896","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459992896?lang=zh_cn&edition=full","pubTime":"2024-08-13 10:10","pubTimestamp":1723515005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399300","300149","688317","BK0216","BK0102","002349","BK0046","300204","BK0077","BK0188","159982","BK0028","BK0239","300026"],"gpt_icon":0},{"id":"2458620852","title":"舒泰神(300204)8月12日主力资金净买入1657.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458620852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458620852?lang=zh_cn&edition=full","pubTime":"2024-08-12 15:17","pubTimestamp":1723447071,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月12日收盘,舒泰神报收于8.07元,上涨16.45%,换手率11.79%,成交量55.6万手,成交额4.32亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:舒泰神2024年一季报显示,公司主营收入9498.34万元,同比上升46.09%;归母净利润-376.94万元,同比上升92.26%;扣非净利润-443.92万元,同比上升90.99%;负债率21.56%,投资收益-6.59万元,财务费用8.88万元,毛利率83.72%。舒泰神主营业务:自主知识产权创新药物,特别是生物药物的研发、生产和营销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200013101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300204","BK0239","BK0046"],"gpt_icon":0},{"id":"2458532137","title":"舒泰神(300204)8月9日主力资金净卖出2241.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458532137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458532137?lang=zh_cn&edition=full","pubTime":"2024-08-09 15:22","pubTimestamp":1723188168,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月9日收盘,舒泰神报收于6.93元,下跌6.48%,换手率5.71%,成交量26.93万手,成交额1.9亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:舒泰神2024年一季报显示,公司主营收入9498.34万元,同比上升46.09%;归母净利润-376.94万元,同比上升92.26%;扣非净利润-443.92万元,同比上升90.99%;负债率21.56%,投资收益-6.59万元,财务费用8.88万元,毛利率83.72%。舒泰神主营业务:自主知识产权创新药物,特别是生物药物的研发、生产和营销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080900025766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300204","BK0046"],"gpt_icon":0},{"id":"2457369212","title":"舒泰神最新公告:STSA-1301皮下注射液取得Ia期临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2457369212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457369212?lang=zh_cn&edition=full","pubTime":"2024-08-08 17:09","pubTimestamp":1723108186,"startTime":"0","endTime":"0","summary":"舒泰神公告,近日,公司取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800034491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0046","BK0239","BK0028"],"gpt_icon":0},{"id":"2457366595","title":"舒泰神(300204.SZ):STSA-1301皮下注射液取得Ia期临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2457366595","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457366595?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:51","pubTimestamp":1723107097,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告,近日,公司取得STSA-1301皮下注射液用于治...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/15.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/15.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1161626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0046","BK0239","STSA","300204","BK4007"],"gpt_icon":0},{"id":"2457365804","title":"舒泰神:取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457365804","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457365804?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:39","pubTimestamp":1723106353,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4007","BK0239","STSA","300204","BK0028","BK0046"],"gpt_icon":0},{"id":"2457354479","title":"舒泰神(300204)8月8日主力资金净买入220.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457354479","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457354479?lang=zh_cn&edition=full","pubTime":"2024-08-08 15:20","pubTimestamp":1723101620,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月8日收盘,舒泰神报收于7.41元,上涨2.92%,换手率8.78%,成交量41.42万手,成交额3.16亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:舒泰神2024年一季报显示,公司主营收入9498.34万元,同比上升46.09%;归母净利润-376.94万元,同比上升92.26%;扣非净利润-443.92万元,同比上升90.99%;负债率21.56%,投资收益-6.59万元,财务费用8.88万元,毛利率83.72%。舒泰神主营业务:自主知识产权创新药物,特别是生物药物的研发、生产和营销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800025025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","300204"],"gpt_icon":0},{"id":"2457683181","title":"A股医药股集体走弱 CRO方向领跌河化股份、百花医药跌停,睿智医药、双成药业、金凯生科、鲁抗医药、四环生物、舒泰神等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457683181","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457683181?lang=zh_cn&edition=full","pubTime":"2024-08-07 09:48","pubTimestamp":1722995301,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159938","BK0239","BK0102","BK0066","BK1574","BK0188","301509","BK0004","600721","09939","000518","BK0046","BK0071","399300","002693","300204","159982","BK0216","BK0145","BK1515","BK0010","300149","BK0168","000953","BK1161","BK0028","600789","BK0077","BK0086"],"gpt_icon":0},{"id":"2457098210","title":"舒泰神(300204)8月6日主力资金净买入314.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457098210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457098210?lang=zh_cn&edition=full","pubTime":"2024-08-06 15:15","pubTimestamp":1722928556,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月6日收盘,舒泰神报收于7.68元,上涨13.78%,换手率10.36%,成交量48.86万手,成交额3.56亿元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:舒泰神2024年一季报显示,公司主营收入9498.34万元,同比上升46.09%;归母净利润-376.94万元,同比上升92.26%;扣非净利润-443.92万元,同比上升90.99%;负债率21.56%,投资收益-6.59万元,财务费用8.88万元,毛利率83.72%。舒泰神主营业务:自主知识产权创新药物,特别是生物药物的研发、生产和营销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600024790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300204","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-04-15","address":"北京市大兴区北京经济技术开发区经海二路36号","stockEarnings":[{"period":"1week","weight":-0.0664},{"period":"1month","weight":0.1351},{"period":"3month","weight":0.0173},{"period":"6month","weight":-0.0596},{"period":"1year","weight":-0.2921},{"period":"ytd","weight":-0.3632}],"companyName":"舒泰神(北京)生物制药股份有限公司","boardCode":"AI0027","perCapita":"16695股","boardName":"医药制造业","registeredCapital":"47777万元","compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0122},{"period":"3month","weight":-0.0817},{"period":"6month","weight":-0.0346},{"period":"1year","weight":-0.0681},{"period":"ytd","weight":-0.0401}],"survey":" 舒泰神(北京)生物制药股份有限公司以自主知识产权创新药物的研发、生产和营销为主要业务,致力于研发、生产和销售临床需求未被满足的治疗性药物,主要包括蛋白类药物(含治疗性单克隆抗体药物)、基因治疗/细胞治疗药物、化学药物三大药物类别,治疗领域覆盖了神经系统相关疾病、感染性疾病、胃肠道疾病、泌尿系统疾病以及自身免疫系统疾病等多种领域。公司上市销售产品为创新生物药物苏肽生(注射用鼠神经生长因子)和全国独家品种舒泰清(复方聚乙二醇电解质散(IV))。苏肽生是我国神经生长因子领域第一个国药准字号产品,是具有自主知识产权的国家一类新药,适应症为“具有促进神经损伤恢复的作用。用于治疗视神经损伤”。苏肽生的两项研发课题被列为“国家十二五重大新药创制项目”;获得北京市科学技术进展三等奖;苏肽生的产业化被列为国家发改委“国家高技术产业发展项目”、国家发改委和经信委联合审评的“重点产业振兴和技术改造专项项目”。","serverTime":1724744682719,"listedPrice":52.5,"stockholders":"28250人(较上一季度减少5.28%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"舒泰神,300204,舒泰神股票,舒泰神股票老虎,舒泰神股票老虎国际,舒泰神行情,舒泰神股票行情,舒泰神股价,舒泰神股市,舒泰神股票价格,舒泰神股票交易,舒泰神股票购买,舒泰神股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}